Volume No. :   9

Issue No. :  4

Year :  2019

ISSN Print :  2231-5705

ISSN Online :  2231-5713


Allready Registrered
Click to Login

A Review on Biopharmaceutical Classification System

Address:   Swati Saxena*, Dr. Sarang Jain
Rajeev Gandhi College of Pharmacy, Bhopal, India
*Corresponding Author
DOI No: 10.5958/2231-5713.2019.00044.8

The biopharmaceutical classification system (BCS) is the result of continuous effort in the mathematical analysis. By this process we can assume kinetics and dynamics of drug in gastrointestinal tract. This process reduces time required to develop a new drug. FDA has published Biopharmaceutical Classification System in order to guide pharmaceutical companies regarding how product qualifies for biowaivers. This can be achieved by avoiding expensive in vivo bioavailability and bioequivalence studies. It helped pharmaceutical companies for easy application of NDA (New drug Application) and ANDA (Abbreviated new drug application) by combining data of drug’s aqueous solubility as well as in vitro dissolution drug release data. The main objective of this article is to make all researchers understand the concept of Biopharmaceutical classification system of drug in a simple manner. So that they can make use of this knowledge in their research work by reducing time in identifying best drug for their formulation.
Biopharmaceutical Classification System, solubility, permeability, dissolution, bioequivalence, immediate-release products.
Swati Saxena, Sarang Jain. A Review on Biopharmaceutical Classification System. Asian J. Pharm. Tech. 2019; 9 (4):267-270.
[View HTML]     

Visitor's No. :   219763